Theseus Pharmaceuticals, Inc.
THRX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.27 | -0.58 | 0.00 |
| FCF Yield | -17.42% | -5.98% | -1.03% | -1.02% |
| EV / EBITDA | -1.87 | -7.69 | -67.73 | -95.14 |
| Quality | ||||
| ROIC | -23.73% | -11.06% | -97.39% | -608.62% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.65 | 1.00 | 0.40 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -22.88% | -460.20% | -0.94% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.68 | 8.95 | 1.24 | 0.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,144.17 | -182,865.00 | -206,590.00 | -52,012.50 |